Literature DB >> 1252669

Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.

F Michal, M Motamed.   

Abstract

1 The interaction of effects between 5-hydroxytryptamine (5-HT) and adenosine diphosphate (ADP) on human or rabbit platelets was investigated in vitro. The initial platelet shape change and their aggregation were measured in stirred, citrated platelet-rich plasma (PRP) at 37 degrees C by recording the rate and extent of changes in light scattering and light transmission. 2 Both the velocity and extent of aggregation and the velocity and extent of the rapid morphological change caused by ADP were enhanced by simultaneous addition of 5-HT. Methysergide but not imipramine inhibited the 5-HT effects. 3 Platelets were made refractory to the aggregating and shape changing effect of either ADP or 5-HT by repeated aggregation with the particular agent; platelets made refractory to ADP retained their responsiveness to 5-HT and platelets made refractory to 5-HT responded to ADP. Platelets pre-incubated for 3-10 min with 5-HT without aggregation showed greatly reduced aggregation on subsequent addition of ADP. Methysergide inhibited all the effects of 5-HT whilst imipramine was inactive. 4 When the shape change or aggregation of platelets induced by ADP was submaximal, addition of 5-HT increased it further. Pre-incubation of PRP with 5-HT before the addition of ADP resulted in failure of the secondary induction of aggregation or shape change by 5-HT. The secondary induction by 5-HT also did not occur in the presence of methysergide; imipramine had no inhibitory effect. Similar secondary induction of aggregation was shown by adrenaline injected during aggregation by ADP; the adrenaline effect was removed by phentolamine but not by propranolol. 5 Our results show that the initial change in shape of platelets and their aggregation can be induced by ADP or 5-HT in specific manner. The interaction of the effect of these substances on platelets can result in either increase in platelet sensitivity or, under certain conditions, decrease in platelet responsiveness. The increase or depression of platelet reactivity appears to be a highly specific effect and is probably mediated at specific receptors involved with platelet activation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1252669      PMCID: PMC1666874          DOI: 10.1111/j.1476-5381.1976.tb07444.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

Review 1.  Release of 5-hydroxytryptamine from blood platelets.

Authors:  M K Paasonen
Journal:  J Pharm Pharmacol       Date:  1965-11       Impact factor: 3.765

Review 2.  Blood platelets as a model for monoamine-containing neurones.

Authors:  J M Sneddon
Journal:  Prog Neurobiol       Date:  1973       Impact factor: 11.685

3.  Transfer and storage of biogenic monoamines in subcellular organelles of blood platelets.

Authors:  A Pletscher; M da Prada; J P Tranzer
Journal:  Prog Brain Res       Date:  1969       Impact factor: 2.453

4.  Effects of 5-hydroxytryptamine on platelet aggregation.

Authors:  H R Baumgartner; G V Born
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

5.  Inhibition of serotonin-induced platelet aggregation in relation to thrombus production.

Authors:  F Michal; F Penglis
Journal:  J Pharmacol Exp Ther       Date:  1969-04       Impact factor: 4.030

6.  D-receptor for serotonin on blood platelets.

Authors:  F Michal
Journal:  Nature       Date:  1969-03-29       Impact factor: 49.962

7.  Platelet shape change and aggregation.

Authors:  J P Caen; H Michel
Journal:  Nature       Date:  1972-11-17       Impact factor: 49.962

8.  Effects of the numbers and sizes of platelet aggregates on the optical density of plasma.

Authors:  G V Born; M Hume
Journal:  Nature       Date:  1967-09-02       Impact factor: 49.962

9.  Platelet aggregation in mammalians (human, rat, rabbit, guinea-pig, horse, dog). A comparative study.

Authors:  Z Sinakos; J P Caen
Journal:  Thromb Diath Haemorrh       Date:  1967-02-28

10.  Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.

Authors:  G V Born; K Juengjaroen; F Michal
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

View more
  7 in total

1.  (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets.

Authors:  D M Bourdon; S K Mahanty; K A Jacobson; J L Boyer; T K Harden
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.

Authors:  D M Vanags; S E Rodgers; E M Duncan; J V Lloyd; F Bochner
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

3.  The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.

Authors:  A Sugidachi; F Asai; T Ogawa; T Inoue; H Koike
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Possible mechanisms of the potentiation of blood-platelet activation by adrenaline.

Authors:  M Bushfield; A McNicol; D E MacIntyre
Journal:  Biochem J       Date:  1987-02-01       Impact factor: 3.857

5.  Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.

Authors:  M Baldacci; M Baldacci; T D Bergel; G V Born; M Hickman
Journal:  Br J Pharmacol       Date:  1980-05       Impact factor: 8.739

6.  Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors?

Authors:  M Graf; A Pletscher
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

7.  Effect of Cordycepin-Enriched WIB801C from Cordyceps militaris Suppressing Fibrinogen Binding to Glycoprotein IIb/IIIa.

Authors:  Dong-Ha Lee; Hyun-Hong Kim; Deok Hwi Lim; Jong-Lae Kim; Hwa-Jin Park
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.